普祺医药递表港交所 中信证券和民银资本担任联席保荐人

Core Viewpoint - Puxi Pharmaceuticals has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities and Minyin Capital serving as joint sponsors [1] Company Overview - Puxi Pharmaceuticals focuses on the immuno-inflammatory field and has developed the world's first JAK inhibitor gel, Pumexitin Gel, for the treatment of atopic dermatitis, which has completed Phase III clinical trials for adults and adolescents aged 12 to 17, and is expanding to children aged 2 to 11 [1] - The company is also developing Pumexitin Nasal Spray, the world's first clinical-stage JAK inhibitor nasal spray for seasonal allergic rhinitis, currently in Phase III clinical trials for adults and expanding to adolescents and adults with perennial allergic rhinitis [1] - PG-033 tablets, a TRPV3 inhibitor with first-in-class potential for pruritus, are in Phase I clinical research, targeting stubborn pruritus related to Omstead syndrome and hyperkeratosis [1] - PG-018 tablets, a JAK1-ROCK dual-target inhibitor for autoimmune kidney disease, are also in Phase I clinical research [1] - PG-040 eye drops, a ROCK-JAK dual-target eye drop, are being developed as a new treatment option for glaucoma [1] Market Potential - The market for drugs treating autoimmune and allergic diseases is experiencing rapid growth both globally and in China [1] - The market for atopic dermatitis drugs in China is projected to grow from 11 billion RMB in 2024 to 50.2 billion RMB by 2033 [1]